Atea Pharmaceuticals, Inc. AVIR 深 沪
已收盘 08-14 16:00:00 美东时间
5.12
+0.050
+0.99%
华盛通- 最 高5.23
- 今 开5.03
- 成交量 25.00万股
- 最 低 4.99
- 昨 收 5.07
- 总市值 4.10亿
- 52周最高 6.45
- 市盈率 静 --
- 换手率 0.31%
- 52周最低 2.78
- 委 比 56.97%
- 总股本 8002.71万
- 历史最高 94.174
- 量 比 0.82
- 振 幅 4.73%
- 历史最低 2.455
- 每 手 1
- 风险率 0.97%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
Morgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Raises Price Target to $7
Morgan Stanley analyst Matthew Harrison maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Equal-Weight and raises the price target from $6 to $7.
08-13 22:15
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Atea Pharmaceuticals reported positive results from its Phase 3 C-BEYOND trial for BEM/RZR in treating chronic hepatitis C virus (HCV), achieving primary and secondary endpoints with an 8-week regimen for non-cirrhotic patients. The company also announced progress in its C-FORWARD trial outside North America and initiated a Phase 1 trial for AT-587 targeting hepatitis E virus (HEV). Financially, Atea reported $219.5 million in cash and investment...
08-12 20:05
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
Atea Pharmaceuticals will host a live conference call and audio webcast on August 12, 2026, at 4:30 p.m. ET to discuss Q2 2026 financial results and provide a business update. Participants can register via the provided link or dial 1-877-407-0779 (U.S.) or 1-201-389-0914 (International) using conference ID 13761501. An audio webcast archive will be available on Atea’s website two hours post-call and remain accessible for 90 days. The company focu...
08-05 11:00
Atea Pharmaceuticals Says Topline Data From C-BEYOND Phase 3 Trial Of Once-daily Fixed-Dose Combination Of Bemnifosbuvir and Ruzasvir for Chronic Hepatitis C Virus Infection Shows Statistical Non-Inferiority Vs. Fixed-Dose Combination Of Sofosbuvir and Velpatasvir
In the mITT analysis (n=905, cirrhotic and non-cirrhotic), BEM/RZR achieved a 93.9% sustained virologic response (SVR) rate vs. 94.8% for SOF/VEL (Epclusa) at Week 24, encompassing SVR at 12 weeks post-treatment (accepted definition of cure for HCV) in both arms. These results achieved the primary e...
07-28 19:09
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
Atea Pharmaceuticals' BEM/RZR achieved statistical non-inferiority to SOF/VEL in treating chronic HCV, with 93.9% SVR in the mITT population. BEM/RZR's 8-week regimen for non-cirrhotic patients showed high cure rates, potentially streamlining treatment and improving patient outcomes. The study highlights BEM/RZR's potential as a best-in-class therapy with fewer drug interactions and flexibility in administration.
07-28 11:00
Atea Pharmaceuticals Initiates First-in-human Phase 1 Clinical Trial Of AT-587 For Hepatitis E Virus Infection
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the initiation of a first-in-human Phase 1 clinical trial evaluating AT-587,...
07-14 19:05
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
Atea Pharmaceuticals has initiated a Phase 1 clinical trial for AT-587, a potential first-in-class oral antiviral treatment for hepatitis E virus (HEV), a serious liver disease with no approved therapies. The trial aims to evaluate safety, tolerability, and pharmacokinetics in healthy volunteers. AT-587 shows high antiviral potency against HEV in preclinical studies and may address a significant unmet need for immunocompromised patients. The stud...
07-14 11:00
Atea Pharma Completes Patient Enrollment In C-FORWARD, Phase 3 Clinical Trial Outside North America, Evaluating Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus Infection
Topline Phase 3 Results from C-FORWARD Expected Around Year-End 2026 More Than 880 HCV Treatment-Naïve Patients Enrolled Across 17 Countries Outside North America C-FORWARD and C-BEYOND Represent the First Global Phase 3 Head-to-Head Trials of Direct-Acting Antivirals for the Treatment of HCV BOSTON...
06-25 19:08
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Atea Pharmaceuticals announced the completion of patient enrollment in its Phase 3 C-FORWARD trial, evaluating the BEM/RZR regimen for treating hepatitis C virus (HCV) in over 880 treatment-naïve patients across 17 countries outside North America. Topline results are expected by year-end 2026. C-FORWARD and C-BEYOND represent the first global Phase 3 head-to-head trials of direct-acting antivirals for HCV. The trials aim to advance the standard o...
06-25 11:00
